TSHZ2: A Promising Potential Drug Target for Ovarian Cancer-Related Protein 10-2

Target Name: TSHZ2

NCBI ID: G128553

TSHZ2

TSHZ2: A Promising Potential Drug Target for Ovarian Cancer-Related Protein 10-2

Ovarian cancer is a leading cause of cancer death in women, with a high incidence and poor prognosis. Despite advances in surgical and radiation treatments, the survival rate for ovarian cancer remains largely the same, and the disease remains a significant public health issue. Therefore, there is a need for new treatments that can offer a more effective and sustainable solution to this problem.

TSHZ2, a protein identified by researchers as ovarian cancer-related protein 10-2 (OCP10-2), has been shown to play a critical role in the development and progression of ovarian cancer. TSHZ2 has also been identified as a potential drug target, which could lead to new treatments for ovarian cancer.

The Identification of TSHZ2 as OCP10-2

TSHZ2 (Tumor suppressor protein 2) is a transmembrane protein that is expressed in various tissues, including the uterus, breast tissue, and tissues of the brain. It has been shown to play a role in cell signaling, and is involved in the regulation of cell growth, differentiation, and apoptosis.

In addition, TSHZ2 has also been shown to be involved in the regulation of the ovarian cycle. It has been shown to play a role in the control of the ovarian follicular epithelium (OE) cell cycle, and is involved in the regulation of the cell division cycle of OE cells.

Recent studies have also shown that TSHZ2 is involved in the regulation of cell survival and apoptosis in ovarian cancer cells. These studies have identified TSHZ2 as a potential drug target for ovarian cancer, due to its involvement in cell signaling and regulation.

The Potential Druggability of TSHZ2

TSHZ2 has been shown to be a potential drug target for ovarian cancer due to its involvement in cell signaling and regulation. Drugs that can inhibit TSHZ2 function have been shown to have potential therapeutic benefits for ovarian cancer.

One approach to inhibiting TSHZ2 function is to target its signaling pathways. TSHZ2 has been shown to be involved in several signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway. Therefore, drugs that can inhibit these pathways could be a potential treatment for ovarian cancer.

Another approach to inhibiting TSHZ2 function is to target its role in cell survival and apoptosis. TSHZ2 has been shown to play a role in the regulation of cell survival and apoptosis in ovarian cancer cells. Therefore, drugs that can inhibit TSHZ2 function and enhance cell apoptosis could be a potential treatment for ovarian cancer.

The Clinical Potential of TSHZ2 as a Drug Target

TSHZ2 has been identified as a potential drug target for ovarian cancer, due to its involvement in cell signaling and regulation. Targeting TSHZ2 function could lead to new treatments for ovarian cancer.

In addition, TSHZ2 has also been shown to be involved in the regulation of the ovarian cycle, which is a critical regulatory process in the development and progression of ovarian cancer. Therefore, drugs that can inhibit TSHZ2 function and enhance ovarian cycle regulation could be a potential treatment for ovarian cancer.

Conclusion

TSHZ2 has been identified as a potential drug target for ovarian cancer due to its involvement in cell signaling and regulation. Targeting TSHZ2 function could lead to new treatments for ovarian cancer. Further research is needed to fully understand the role of TSHZ2 in ovarian cancer and to develop effective drugs that can inhibit its function.

Protein Name: Teashirt Zinc Finger Homeobox 2

Functions: Probable transcriptional regulator involved in developmental processes. May act as a transcriptional repressor (Potential)

The "TSHZ2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TSHZ2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets